Early Bird registration extended to June 14.
Immunotherapy has revolutionized the treatment of cancer, as PD-1 blockade and CAR-T cell therapies are becoming the standard of care in many disease settings. However the field needs to learn much more about the basic biology of immunoregulation as well as the response and resistance mechanisms in patients to bring this to the next level. Several topics that will be highlighted include:
- Strategies to improve anti-tumor immunity
- Insights into immunoregulation
- Novel cell subsets
- Autoimmunity as a consequence of PD-1 blockade
- Insights from clinical trials
Keynote speakers:
- Tasuku Honjo (Kyoto University, Japan) Nobel Prize in Physiology or Medicine 2018 recipient
- Jan Joseph Melenhorst (University of Pennsylvania, US)
- Jedd D. Wolchok (Memorial Sloan Kettering Cancer Center, US)